San Diego‑based Iambic reported that physics‑informed algorithms plus lab automation are delivering small molecules through to clinic in roughly two years. The company combines AI‑driven design, automated synthesis and integrated biology to shorten the traditional chemistry timeline, and has started attracting industry partners as its platform progresses toward clinic‑ready candidates. Iambic’s approach reflects growing investor and partner interest in tightening the discovery‑to‑IND gap through compute‑wet‑lab integration; the company is positioning the platform as a faster, reproducible route for lead generation and candidate selection.